OXiGENE gets European patent for OXi4503 in AML and other myeloid malignancies
The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
The project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, as well as the use of evidence-based guidelines.